Actively Recruiting
Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
Led by Université de Sherbrooke · Updated on 2026-02-10
40
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
U
Université de Sherbrooke
Lead Sponsor
I
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the relationship between changes in fat tissue metabolism and the remission of Type 2 Diabetes (T2D) following bariatric surgery. This study involves adults aged 18 to 65 with or without T2D, divided into two groups to compare metabolic differences after surgery. The primary goal is to understand if improved fat storage contributes to the rapid improvement of liver and heart metabolism after the procedure. Participants will undergo laparoscopic sleeve gastrectomy as the bariatric surgery method. The study includes five visits: a screening visit and four detailed metabolic sessions before and after surgery. These sessions involve consuming a liquid meal, receiving stable tracer infusions, and undergoing PET and MRI scans. During one session before surgery, participants receive niacin to assess its effect on fat metabolism. Metabolic sessions occur before surgery, 12 days post-surgery, and one year after surgery. Throughout the study, participants will be monitored during these metabolic visits lasting 9 hours each, involving tracer perfusions, imaging scans, and blood tests. Researchers will measure fat uptake and processing in various tissues, glucose production, insulin secretion, and other metabolic and hormonal responses. The study will track changes from baseline to one year after surgery to understand the metabolic mechanisms related to T2D remission.
CONDITIONS
Brief Title
Adipose Tissue Storage in the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 65
- Body mass index (BMI) of 35 kg/m2
- Diagnosed with Type 2 Diabetes according to Diabetes Canada criteria or diagnosed without Type 2 Diabetes
- Women must have a negative serum pregnancy test
You will not qualify if you...
- Currently using oral contraceptives
- Treatment with fibrate, thiazolidinedione, insulin, or beta-blocker that cannot be stopped temporarily or has long-lasting effects
- Presence of overt cardiovascular disease, liver or kidney failure, or other uncontrolled medical conditions
- Any contraindications to surgery or temporarily stopping diabetes, lipid, or hypertension medications
- Smoking or consuming more than 2 alcoholic drinks per day
- Contraindication to MRI
- Diabetes Remission (DiaRem) score greater than 8
- Participation in a research study with radiation exposure within the last two years
- Pregnant or breastfeeding women
- Weight over 200 kg exceeding MRI and PET scanner limits
- Allergy to eggs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 1 week interval between sessions
Participants undergo two metabolic sessions before surgery to assess metabolic function, including stable tracer perfusion, ingestion of a liquid meal, PET, and MRI scans. One session includes administration of nicotinic acid to regulate lipid metabolism.
2 visits, each lasting approximately 9 hours
Duration - Single day procedure with recovery
Participants undergo laparoscopic sleeve gastrectomy surgery.
1 visit (surgery day)
Duration - 1 day
Participants complete a metabolic session 12 days after surgery to assess post-surgical metabolic changes without nicotinic acid administration.
1 visit lasting approximately 9 hours
Duration - 1 day
Participants complete a metabolic session 1 year after surgery to evaluate long-term metabolic outcomes without nicotinic acid administration.
1 visit lasting approximately 9 hours
Trial Site Locations
Total: 1 location
1
centre de recherche du CHUS
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
Research Team
F
Frédérique Frisch
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here